H. de Graaf

498 total citations
25 papers, 342 citations indexed

About

H. de Graaf is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, H. de Graaf has authored 25 papers receiving a total of 342 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in H. de Graaf's work include Cancer Treatment and Pharmacology (11 papers), Breast Cancer Treatment Studies (7 papers) and Advanced Breast Cancer Therapies (6 papers). H. de Graaf is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Breast Cancer Treatment Studies (7 papers) and Advanced Breast Cancer Therapies (6 papers). H. de Graaf collaborates with scholars based in Netherlands, United States and New Zealand. H. de Graaf's co-authors include A.N.M. Wymenga, Caroline Seynaeve, Harm van Tinteren, J.W.R. Nortier, A. Elise van Leeuwen‐Stok, Elisabeth G.E. de Vries, Maartje Los, Marije E. Hamaker, Felix E. de Jongh and J.J. Braun and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

H. de Graaf

25 papers receiving 326 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
H. de Graaf Netherlands	10	176	89	84	83	53	25	342
Elena Zafarana Italy	10	121 0.7×	53 0.6×	96 1.1×	124 1.5×	73 1.4×	17	347
Marjan Emami Canada	8	55 0.3×	128 1.4×	58 0.7×	49 0.6×	44 0.8×	11	324
Nitya Nathwani United States	12	186 1.1×	27 0.3×	61 0.7×	39 0.5×	42 0.8×	37	528
Leanne Goldstein United States	13	104 0.6×	50 0.6×	54 0.6×	38 0.5×	43 0.8×	21	320
L. Winterbottom United Kingdom	10	216 1.2×	66 0.7×	62 0.7×	198 2.4×	16 0.3×	25	360
Jacques Cretin France	7	171 1.0×	86 1.0×	84 1.0×	48 0.6×	60 1.1×	9	328
Anatole Cessot France	12	328 1.9×	195 2.2×	23 0.3×	81 1.0×	69 1.3×	30	562
J Crétin France	8	94 0.5×	72 0.8×	30 0.4×	30 0.4×	26 0.5×	31	257
Sungjin Kim South Korea	9	169 1.0×	150 1.7×	22 0.3×	53 0.6×	18 0.3×	17	409
Guillaume Beinse France	12	125 0.7×	93 1.0×	22 0.3×	160 1.9×	9 0.2×	33	361

Countries citing papers authored by H. de Graaf

Since Specialization

Citations

This map shows the geographic impact of H. de Graaf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. de Graaf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. de Graaf more than expected).

Fields of papers citing papers by H. de Graaf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. de Graaf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. de Graaf. The network helps show where H. de Graaf may publish in the future.

Co-authorship network of co-authors of H. de Graaf

This figure shows the co-authorship network connecting the top 25 collaborators of H. de Graaf. A scholar is included among the top collaborators of H. de Graaf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. de Graaf. H. de Graaf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Noordman, Bo Jan, H. de Graaf, Irene E.G. van Hellemond, et al.. (2025). The prognostic value of peritoneal metastases in patients with gastric cancer: a nationwide population-based study. EClinicalMedicine. 81. 103109–103109. 1 indexed citations

Tjan-Heijnen, V.C.G., Sandra M. E. Geurts, Ingeborg J. H. Vriens, et al.. (2022). 133O Extended adjuvant aromatase inhibition after sequential endocrine therapy: Final results of the phase III DATA trial. Annals of Oncology. 33. S599–S599. 3 indexed citations

Erdkamp, Frans, Marta López‐Yurda, Harm van Tinteren, et al.. (2019). Intermittent versus continuous chemotherapy beyond first-line for patients with HER2-negative advanced breast cancer (BOOG 2010-02). Annals of Oncology. 30. iii50–iii51. 1 indexed citations

Bos, Monique E.M.M., Marta López‐Yurda, A.H. Honkoop, et al.. (2017). Efficacy of two times four versus continuous eight cycles of paclitaxel/bevacizumab as first-line chemotherapy in metastatic breast cancer: The Stop&Go study of the Dutch Breast Cancer Research Group (BOOG). Annals of Oncology. 28. v78–v79. 1 indexed citations

Smorenburg, Carolien H., A. Elise van Leeuwen‐Stok, Marije E. Hamaker, et al.. (2014). A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG. Annals of Oncology. 25(3). 599–605. 43 indexed citations

Hamaker, Marije E., Caroline Seynaeve, A.N.M. Wymenga, et al.. (2013). Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: Results from the OMEGA study of the Dutch Breast Cancer Trialists' Group. The Breast. 23(1). 81–87. 108 indexed citations

Reyners, A.K.L., Linda de Munck, Frans Erdkamp, et al.. (2012). A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study. Annals of Oncology. 23(11). 2896–2902. 34 indexed citations

Seynaeve, C., Harm van Tinteren, A.N.M. Wymenga, et al.. (2012). 249 Feasibility and Toxicities Associated with PEG Doxo Versus Capecitabine as First-line Chemotherapy in Elderly Metastatic Breast Cancer (MBC) Patients; Results From the Randomized OMEGA Study of the Dutch Breast Cancer Trialists’ Group (BOOG). European Journal of Cancer. 48. S115–S115. 1 indexed citations

Graaf, H. de, et al.. (2011). Cyclophosphamide-induced symptomatic hyponatraemia.. PubMed. 69(4). 192–5. 14 indexed citations

10.

Jager, Agnes, SC Linn, H. de Graaf, et al.. (2011). PD07-07: Combination of Paclitaxel and Bevacizumab without or with Capecitabine as First-Line Treatment of HER2−Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): First Results from a Randomized, Multicenter, Open-Label, Phase II Study of the Dutch Breast Cancer Trialists' Group (BOOG).. Cancer Research. 71(24_Supplement). PD07–7. 4 indexed citations

11.

Kroep, Judith R., Sabine C. Linn, Epie Boven, et al.. (2010). Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer.. PubMed. 68(9). 371–6. 13 indexed citations

12.

Reyners, Anna K.L., Willem M. Smit, Michael Schaapveld, et al.. (2009). Adding the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin in first line for stage IC-IV epithelial ovarian cancer: A randomized phase II study. Journal of Clinical Oncology. 27(15_suppl). 5545–5545. 1 indexed citations

13.

Munck, Linda de, G.J. Creemers, H. de Graaf, et al.. (2007). A phase III study on the efficacy and safety of docetaxel, every three weeks or as a weekly regimen in patients with metastatic breast cancer. Breast Cancer Research and Treatment. 106. 1 indexed citations

14.

Vos, Filip De, Michael Schaapveld, C.A.M. de Swart, et al.. (2005). A randomized phase II study of paclitaxel with carboplatin ± amifostine as first line treatment in advanced ovarian carcinoma. Gynecologic Oncology. 97(1). 60–67. 28 indexed citations

15.

Hovenga, Sjoerd, H. de Graaf, Peter Joosten, et al.. (2003). Enteropathy-associated T-cell lymphoma presenting with eosinophilia.. PubMed. 61(1). 25–7. 7 indexed citations

16.

Vries, Elisabeth G.E. de, et al.. (2000). True. British Journal of Cancer. 82(12). 1920–1924. 2 indexed citations

17.

Graaf, H. de, et al.. (1997). Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer. British Journal of Cancer. 76(7). 943–945. 17 indexed citations

18.

Graaf, H. de, Pax H.B. Willemse, & Dirk Th. Sleijfer. (1994). Review: Breast Cancer in Elderly Patients. Age and Ageing. 23(5). 427–434. 3 indexed citations

19.

Graaf, H. de, P.H.B. Willemse, Elisabeth G.E. de Vries, et al.. (1994). Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes. European Journal of Cancer. 30(2). 150–153. 23 indexed citations

20.

Mees, E. J. Dorhout & H. de Graaf. (1973). Free Water Clearance in Patients with Essential Hypertension. Clinical Science. 45(4). 469–477. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact